

1 **Title:** Hydroxychloroquine and mortality risk of patients with COVID-19: a systematic review and
2 meta-analysis of human comparative studies

3
4 Thibault Fiolet^{1,2*}, Anthony Guihur³, Mathieu Rebeaud³, Matthieu Mulot⁴, Yahya Mahamat-Saleh^{1,2}

5
6
7 ¹CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris
8 Saclay, 94 805, Villejuif, France

9 ²Gustave Roussy, F-94805, Villejuif, France

10 ³Department of Plant Molecular Biology, Faculty of Biology and Medicine, University of Lausanne,
11 Switzerland

12 ⁴Laboratory of Soil Biodiversity, Faculty of Science, University of Neuchâtel, Switzerland.

13
14 **Corresponding author:**

15 *Thibault Fiolet, MSc, PhD candidate in Epidemiology

16 Center for Research in Epidemiology and Population Health

17 Inserm U1018 “Health across Generations” Team and Paris-Sud 11 University/Paris-Saclay University

18 114 rue Edouard Vaillant

19 94805 Villejuif Cedex

20 E-mail: Thibault.fiolet@gustaveroussy.fr

21 Twitter: [@T_Fiolet](https://twitter.com/T_Fiolet)

22
23 **Last name and degree of authors:**

24 Fiolet, *MPH*, Rebeaud, Msc, Guihur, *PhD*, Mulot, *PhD*, Mahamat-Saleh, *MPH*,

25
26 **Abbreviations:** HCQ: Hydroxychloroquine; AZ: Azithromycin; RR: Relative Risk; HR: Hazard
27 Ratio, OR: Odds Ratio; US FDA: US Food and Drug Administration; EMA: European Medicine
28 Agency, CI: Confidence Interval

29
30 **Contributors:** TF designed the research. TF, MR, AG, MM and YMS conducted the research. TF did
31 the statistical analysis. TF wrote the first draft of the paper. MR, AG, MM and YMS contributed to the
32 writing of the paper. All authors contributed to the data interpretation, revised each draft for important
33 intellectual content, and read and approved the final manuscript.

34
35 **Competing interests:** All authors declare: no support from any organisation for the submitted work
36 other than that described above; no financial relationships with any organisations that might have an
37 interest in the submitted work in the previous three years; no other relationships or activities that could
38 appear to have influenced the submitted work.

39
40
41 **Word count: 3,589**

42
43 **Number of figures: 3**

44 **Number of tables: 2**

45 **Supplemental material:**

46 Supplementary Figures: 8

47 Supplementary Tables: 2

48 Supplementary File: 1 Excel file

49
50 **Keywords:** COVID-19; SARS-CoV-2 ; hydroxychloroquine ; mortality ; meta-analysis ; azithromycin

51
52
53 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

54 **Background:** Global COVID-19 deaths reached at least 400,000 fatalities. Hydroxychloroquine is an
55 antimalarial drug that elicit immunomodulatory effects and had shown in vitro antiviral effects against
56 SRAS-CoV-2. This drug divided opinion worldwide in the medical community but also in the press,
57 the general public and in public health policies. The aim of this systematic review and this meta-
58 analysis was to bring a new overview on this controversial drug and to assess whether
59 hydroxychloroquine could reduce COVID-19 mortality risk in hospitalized patients.

60
61 **Methods and Findings:** Pubmed, Web of Science, Cochrane Library, MedRxiv and grey literature
62 were searched until 10 June 2020. Only studies of COVID-19 patients treated with
63 hydroxychloroquine (with or without azithromycin) compared with a comparative standard care group
64 and with full-text articles in English were included. Studies reporting effect sizes as Odds Ratios,
65 Hazard Ratio and Relative Risk for mortality risk and the number of deaths per groups were included.
66 This meta-analysis was conducted following PRISMA guidelines and registered on PROSPERO
67 (Registration number: CRD42020190801). Independent extraction has been performed by two
68 independent reviewers. Effect sizes were pooled using a random-effects model.

69
70 The initial search led to 112 articles, from which 16 articles met our inclusion criteria. 15 studies
71 were retained for association between hydroxychloroquine and COVID-19 survival including 15,081
72 patients (8,072 patients in the hydroxychloroquine arm and 7,009 patients in the standard care arm
73 with respectively, 1,578 deaths and 1,423 deaths). 6 studies were retained for hydroxychloroquine
74 with azithromycin. Hydroxychloroquine was not significantly associated with mortality risk (pooled
75 Relative Risk RR=0.82 (95% Confidence Interval: 0.62-1.07, $I^2=82$, $P_{\text{heterogeneity}} < 0.01$, $n=15$)) within
76 hospitalized patients, nor in association with azithromycin (pooled Relative Risk RR=1.33 (95% CI:
77 0.92-1.92, $I^2=75\%$, $P_{\text{heterogeneity}} < 0.01$, $n=6$)), nor in the numerous subgroup analysis by study design,
78 median age population, published studies (vs unpublished articles), level of bias risk. However,
79 stratified analysis by continents, we found a significant decreased risk of mortality associated with
80 hydroxychloroquine alone but not with azithromycin among European (RR= 0.62 (95%CI: 0.41-0.93,
81 $n=7$)) and Asian studies (RR=0.36 (95%CI:0.18-0.73, $n=1$)), with heterogeneity detected across
82 continent ($P_{\text{heterogeneity between}}=0.003$). These finding should be interpreted with caution since several
83 included studies had a low quality of evidence with a small sample size, a lack of adjustment on
84 potential confounders or selection and intervention biases.

85
86 **Conclusion:** Our meta-analysis does not support the use of hydroxychloroquine with or without
87 azithromycin to reduce COVID-19 mortality in hospitalized patients. It raises the question of the
88 hydroxychloroquine use outside of clinical trial. Additional results from larger randomised controlled
89 trials are needed

90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108

Introduction

109 On December 31, 2019, World Health Organization (WHO) identified in Wuhan (China) an unknown
110 pneumonia caused by a new coronavirus, SARS-CoV-2. This new coronavirus rapidly spread around
111 the world and on the 11th of March, the WHO declared it as a pandemic. By 17 June, 2020, WHO
112 confirmed 8,006,427 cases and 436,899 deaths.

113
114 Recent publications identified the *in vitro* antiviral activity against SARS-CoV-2 of
115 hydroxychloroquine (HCQ), an aminoquinoline like chloroquine. HCQ appeared as a potential
116 treatment for COVID-19 patients at low costs(1). HCQ is also used as antimalarial drug, for
117 rheumatoid arthritis and for lupus. This drug was widely advertised by international press and the
118 United States President(2). Three *in vitro* studies tested HCQ on VeroE6 cells infected by SARS-CoV-
119 2. This later suggested that HCQ decreased the viral replication with 50% inhibitory concentration
120 (IC50) values of 2.2 μM (0.7 $\mu\text{g}/\text{mL}$) and 4.4 μM (1.4 $\mu\text{g}/\text{mL}$) in Maisonnasse *et al.* study, at 0.72 μM
121 in Yao *et al.* study and between 4.51 – 12.96 μM for 50% maximal effective concentration (EC50) in
122 Liu *et al.* study (1–3). Another study reported a synergistic effect of the HCQ with azithromycin (AZ)
123 against SARS-CoV-2(6). The mechanism would be an acidification of the endosomes pH, and this pH
124 modification would block the virus-endosome fusion (7).

125
126 Hydroxychloroquine was also tested in a study where macaques were infected by SARS-CoV-2 and
127 received either a high dose of hydroxychloroquine (90 mg/kg on day 1 then 45 mg/kg) either a low
128 HCQ dose (30 mg/kg on day 1 then 15 mg/kg) (3). Hydroxychloroquine did not improve the time to
129 viral clearance. Another study in preprint also reported that there is no evidence of efficacy for the
130 drug hydroxychloroquine (6.5 mg/kg) against infection with SARS-CoV-2 in hamsters or macaque
131 models(8).

132
133 By June 17, about 132 trials have been referenced to test hydroxychloroquine for COVID-19 on
134 ClinicalTrials.gov (9). Until today, most of the published studies on hydroxychloroquine with a
135 comparative group (standard care) were observational and non-randomized with inconsistent results
136 (10–16). This study is the first meta-analysis to pool adjusted relative risk and to include 16 studies.
137 Previous meta-analysis on COVID-19 included a very limited number of studies and used unadjusted
138 risk ratio (17–19). Thus, the aim of this meta-analysis was to provide a systematically quantitative
139 assessment of the association between HCQ treatment (vs standard care) and COVID-19 survival risk
140 among human trials and observational studies.

141
142

143 **Material and methods**

144 **Data sources, search strategy**

145 Research question was: does hydroxychloroquine treatment (vs standard care) have an effect (positive
146 or negative) on survival of patients with COVID-19? A search was performed via PubMed and Web of
147 Science and Cochrane Review until 10 June 2020 with this string search: (COVID-19 OR SRAS-CoV-
148 2) AND (MORTALITY OR DEATH) AND (HYDROXYCHLOROQUINE OR HCQ)
149 (Supplementary text S1). Given that the number of articles about hydroxychloroquine and COVID-19
150 is rapidly growing, we also manually searched additional reference on MedRxiv preprint server and on
151 google scholar. The language was limited to English. This meta-analysis was conducted following
152 PRISMA statements in Supplementary text S2. This study has been recorded on the international
153 database of prospectively registered systematic reviews, PROSPERO (Registration number:
154 CRD42020190801).

155
156
157
158

159 **Criteria for study selection:**

160 Inclusion criteria were 1) reports must contain original data with available risk estimates (Hazard
161 Ration, Odds Ratios, Relative Risk and/or with data on the number of death in HCQ and control
162 groups 2) all publication dates will be considered 3) publications in English language 4) comparative
163 studies with a control group without hydroxychloroquine and 5) COVID-19 confirmed cases by RT-
164 PCR. Reviews and meta-analysis, commentaries, *in vitro* and *in vivo* studies were excluded.

165

166 **Data extraction**

167 Data extraction was performed by two investigators (Mr. T. Fiolet and Mr. Y. Mahamat-Saleh) who
168 screened the titles and abstracts. Discrepancies were resolved by a third investigator (Dr. Anthony
169 Guihur).

170 The following data were extracted from each study: study design, publication date, location, number
171 of participants (total, in treatment and control groups, doses when available, effect size (Hazard Ratio,
172 Odds Ratio or Relative Risk) and 95% confidence intervals for reported risk estimates. Hazard Ratio
173 (HR) refers to the ratio of hazards in the intervention group divided by those occurring in the control
174 group. Hazard represents the instantaneous event rate, which means the probability that an individual
175 would experience an event (e.g. death) at a particular given point in time after the intervention,
176 assuming that this individual has survived to that particular point of time without experiencing any
177 event. In contrast, Relative Risk (RR) and Odds Ratio (OR) does not take account of the timing of
178 each event. RR and OR are similar when the event (death) is rare. The most adjusted effect size
179 reflecting the greatest control of potential confounders was extracted.

180 Three included studies did not report effect size for mortality risk (15,20,21). Thus we used the
181 number of death per groups to calculate an unadjusted relative risk using *metabin* function in *meta*
182 package in R Software (22). RR calculation is based on Cochrane Handbook for Systematic Reviews

183 of Interventions formula $RR = \frac{\frac{\text{number of deaths in treatment group}}{\text{number of participants in treatment group}}}{\frac{\text{number of deaths in control group}}{\text{number of participants in control group}}}$ (23)

184 For all the other studies, reported adjusted OR, RR or HR were used. The quality of each study was
185 assessed with ROBIN-I tool following Cochrane guidelines for non-randomized studies and with Rob2
186 for randomized studies (24,25).

187

188 **Outcome**

189 The outcome is COVID-19 mortality.

190

191 **Statistical analysis**

192 Effect of HCQ alone and HCQ + AZ

193 A primary meta-analysis was performed to assess the association between hydroxychloroquine alone
194 (vs standard care) and risk of death. In a second time, the relationship between hydroxychloroquine
195 associated with azithromycin and mortality was assessed. HRs, ORs and RRs were treated as
196 equivalent measures of mortality risk. Pooled RRs were determined by using a random effect model
197 with inverse variance weighting (DerSimonian-Laird method) (26). Significance was checked by Z-
198 test ($p < 0.05$ was considered as significant).

199

200 Heterogeneity was assessed by the Chi-square test and I^2 test. $30\% < I^2 < 60\%$ was interpreted as
201 moderate heterogeneity and $I^2 > 60$ as high heterogeneity. Funnel plot was constructed to assess the
202 publication bias. Begg's and Egger's test were conducted to assess the publication bias (7,27). RR or
203 HR and their 95% confidence interval were used to assessed mortality risk.

204

205

206

207 **Subgroup analysis**

208 Subgroup analyses were further conducted according to the quality assessment to explore the source of
 209 heterogeneity among observational studies. We performed stratified analyses by continents, the type
 210 of article (peer-reviewed vs unpublished), the use of an adjustment on confounding factors (studies
 211 with $RR_{unadjusted}$ vs $RR_{adjusted}$), the mean daily dose of hydroxychloroquine (continuous), the median
 212 population age across the studies (median age > 63 years) and the level of bias risk identified with
 213 ROBIN-I (moderate/serious/critical) (24), the exclusion of studies with cancer and dialysis patients.
 214 Mean daily dose of hydroxychloroquine is a daily average between the loading dose and the
 215 maintenance doses. Additionally, influence analysis was conducted by omitting each study to find
 216 potential outliers (28). It is used to detect studies which influence the overall estimate of our meta-
 217 analysis the most, omitting one study at a time (leave-one-out method).

218
 219

220 A two-sided p-value < 0.05 was considered statistically significant. All analysis were conducted using
 221 R version 3.6.1 with *meta* package and *robvis* package (29).


222

223 **Results**

224 **Literature Search**

225 After searching Pubmed and Web of Science, 105 results were identified. 7 articles from
 226 Medrxiv/Google Scholar were added. After screening the title and the abstract, only 9 articles about
 227 hydroxychloroquine and COVID-19 were included. 144 articles were excluded for not meeting the
 228 inclusion criteria. 16 articles were included for further consideration including 14 observational
 229 studies and one non-randomized trial and one unpublished randomized controlled trial (RCT): 15
 230 articles for HCQ (10–17,20,21,30–34) and 6 articles for HCQ+AZ (10,16,30,31,35,36). Flow chart is
 231 presented in Figure 1.

232



233

234 Figure 1: Flow diagram of study selection process

235

236 **Study characteristics**

237 This meta-analysis includes 8,072 patients in the hydroxychloroquine group and 7,009 patients in the
238 standard care group with respectively 1,578 deaths and 1,423 deaths. Individual studies are described
239 in Table 1. It appears that all the included studies were carried on hospitalized patients. No study
240 meeting our inclusion criteria addressed the effect of HCQ on asymptomatic forms of COVID-19.
241 Mean and median age of participants ranged from 53 to 72 across the studies. Studies were conducted
242 in the USA (n=6) (13,16,20,30,31,36), in Spain (n=4) (14,15,33,35), in France (n=2) (11,21), in the
243 UK (n=1)(37), in Italy (n=1) (32), in China (n=1) (12) and in 3 countries (USA, Canada and
244 Spain)(10). 9 articles were published, and 4 articles were preprints. RECOVERY Trial data were
245 reported by a press communication (34,37). Mean daily dose of hydroxychloroquine ranged from 333
246 mg/j to 945 mg/j.

247

248

249

First Author	Journal	Type of study	Country	Number of deaths		Number of participants		Treatment	Mean HCQ dose per day	Age ^a (years)	Patients	Study quality
				Control	HCQ	Control	HCQ					
Alberici et al(32), 2020	Kidney International	Observational, cohort	Italy	Not reported	Not reported	22	72	Not specified	NA	72 (median) IQ=62-79	Hospitalized patients with haemodialysis	Critical
Ayerbe et al(15), 2020	Journal of Thrombosis and Thrombolysis	Observational, cohort	Spain	49	237	162	1857	Not specified	NA	67,57 (mean)	Hospitalized patients	Serious
Barbosa Joshua et al(20), 2020	Unpublished	Observational, cohort	USA	1	2	21	17	800 mg for 2 days then 200-400mg for 3-4 days	600	62.7 (mean) SD=15.1	Hospitalized patients (mild/moderate symptoms)	Critical
Geleris et al(13), 2020	NEJM	Observational, cohort	USA	75	157	565	811	1200mg at day 1 then 400mg for 4 days	560	From <40 to >80	Hospitalized patients (moderate/severe symptoms)	Moderate
Ip et al(31), 2020	PrePrint	Observational, cohort	USA	115	432	598	1914	800mg at day 1 then 400mg on day 2-5 (80%)	400	64 (median) IQ=52-76	Hospitalized patients (44% moderate/severe symptoms)	Moderate
Kuderer et al(10), 2020	The Lancet	Observational, cohort	USA Canada Spain	41	11	486	89	Not specified	NA	66 (median) IQ=57-76	Hospitalized patients with who have a current or past diagnosis of cancer	Moderate
Magagnoli et al(30), 2020	Clinical Advances	Observational, cohort	USA	37	38	395	198	Median HCQ dose: 400mg/day Median HCQ+AZ dose: 422.2 mg/day	400	70 (median) IQ=60-75	Hospitalized patients	Serious
Mahevas et al(11), 2020	BMJ	Observational, cohort	France	8	9	89	84	600mg/day	600	60 (median) IQ=52-68	Hospitalized patients with covid-19	Moderate

											pneumonia who require oxygen:	
Membrillo et al(14), 2020	PréPrint	Observational, cohort	Spain	21	27	43	123	Loading dose of 800 mg + 400 mg in following days (ten days for moderate cases)	440	HCQ: 61.5 No HCQ: 68.7 (mean)	Hospitalized patients	Serious
Philippe Gautret et al(21), 2020	International Journal of Antimicrobial Agents	Non-randomised controlled trial	France	0	1	16	26	A maintenance dose of 600 mg/day	600	45,1 (mean) SD=22	Hospitalized patients (mild symptoms)	Critical
RECOVERY TRIAL	Unpublished	Randomized controlled trial	UK	736	396	3132	1542	A loading dose of 2400mg at day 1, then 800mg/day for 10 days	945	Not specified	Hospitalized patients	Not applicable
Rogado et al(35), 2020	Clinical and Translational Oncology	Observational, cohort	Spain	Not reported	Not reported	8	18	Not specified	NA	71 (median) Range:34-90	Hospitalized patients (64% severe cases)	Critical
Rosenberg et al(16), 2020	JAMA	Observational, cohort	USA	28	54	221	271	400mg then 200-400mg at 2nd prescription then 200-400mg at 3rd	333	63 (median)	Hospitalized patients	Moderate
Sanchez-Alvarez et al(33), 2020	Nefrología	Observational, cohort	Spain	32	166	53	322	Not specified	NA	71 SD=15	(85%) required hospital admission, 8% in intensive care units, with haemodialysis	Serious
Singh et al(36), 2020	PrePrint	Observational, cohort	USA	104	109	910	910	Not specified	NA	62 SD=17	Hospitalized patients	Serious
Yu et al(12),	Science	Observational,	China	238	9	502	48	400mg during	NA	68 (median)	Critically ill	Serious

2020	China Life Sciences	cohort						7-10 days		IQ: 59-77	patients	
------	---------------------	--------	--	--	--	--	--	-----------	--	-----------	----------	--

Table 1 (continued): Characteristics of studies included in the meta-analysis for COVID-19 mortality
 IQ=Interquartile range, SD=Standard Deviation, HCQ=Hydroxychloroquine, AZ=Azithromycine, NA=Not available

First Author	Effect size reported in each study ^b	Adjustments	Treatment	Control
Alberici et al(32), 2020	OR=0,44 [0,16-1,24]	Not adjusted	HCQ alone	Other antiviral and antibiotic were administered
Ayerbe et al(15), 2020	RR _{calculated} =0,422 [0,325-0,546]	Not adjusted	HCQ alone	Other antiviral and antibiotic were administered
Barbosa Joshua et al(20), 2020	RR _{calculated} =2,47 [0,24-24,98]	Not adjusted	HCQ alone	Supportive care
Geleris et al(13), 2020	HR=1,04 [0,82-1,32]	inverse probability weighting from a propensity-score	HCQ alone	Standard care not specified
Ip et al(31), 2020	HR=0.99 [0.8-1.22] HR=0.98 [0.75-1.28]	Cox model adjusted on the propensity-score variable: gender, coronary disease, stroke, heart failure, arrhythmia, African American, COPD, , renal failure, rheumatologic disorder, inflammatory bowel disease, advanced liver disease, age, diabetes mellitus, insulin use prior to hospitalization, asthma, HIV/hepatitis, any cancer, and log ferritin	HCQ alone HCQ+AZ	Group without drug
Kuderer et al(10), 2020 ^c	OR=1,06 [0,51,2,2] OR=2.93 [1.79-4.79]	Adjusted for age, sex, smoking status, and obesity	HCQ alone HCQ+AZ	Treatment without AZ
Magagnoli et al(30), 2020	HR=1.83 [1.16-2.89] HR=1.31 [0.80-2.15]	Propensity score adjustment. All baseline covariates were included in the propensity score models (age, race, BMI, SpO2, breaths per minute, heart rate, T°, systolic blood pressure, ALT, AST, serum albumin, Total bilirubin, Creatinine, Erythrocytes, Haematocrit, Leukocytes, Lymphocytes, Platelets, Blood urea nitrogen, C-reactive protein	HCQ alone HCQ+AZ	Standard care
Mahevas et al(11), 2020	HR=1,2 [0,4,3,3]	Inverse probability of treatment weighting in Cox model. age, sex, comorbidities (presence of chronic respiratory insufficiency during oxygen treatment, or asthma, cystic fibrosis, or any chronic respiratory disease likely to result in decompensation during a viral infection; heart failure (New York Heart Association class III or IV); chronic kidney disease; liver cirrhosis with Child-Pugh class B or more; personal history of cardiovascular disease (hypertension, stroke, coronary artery disease, or cardiac surgery); insulin dependent diabetes mellitus, or	HCQ alone	Standard care

		diabetic microangiopathy or macroangiopathy; treatment with immunosuppressive drugs, including anticancer chemotherapy; uncontrolled HIV infection or HIV infection with CD4 cell counts <200/ μ L; or a haematological malignancy); body mass index (≥ 30 or not); third trimester of pregnancy; treatment by angiotensin converting enzyme inhibitors or angiotensin receptor blockers ¹³ ; time since symptom onset; and severity of condition at admission (percentage of lung affected: $\geq 50\%$ or not; presence of confusion; respiratory frequency; oxygen saturation without oxygen; oxygen flow; systolic blood pressure; and C reactive protein level).		
Membrillo et al(14), 2020	OR=0,07 [0,012,0,402]	Adjusted on variables with $p < 0,25$ in univariate analysis	HCQ alone	Standard care + other antivirals, immunomodulators, anti-inflammatory drugs
Philippe Gautret et al(21), 2020	RR _{calculated} =3,41 [0,1505,77,45]	Not adjusted	HCQ alone	Group without HCQ
RECOVERY TRIAL	HR=1,1 [0,98,1,26]	Adjustment not precised	HCQ alone	Standard care
Rogado et al(35), 2020	OR=0,02 [0,01,0,73]	Adjusted by median age, histology, staging, cancer treatment received and hypertension	HCQ+AZ	Group without HCQ
Rosenberg et al(16), 2020	HR=1,08 [0,63,1,85] HR=1.35 [0.76-2.4]	Multiple adjustments on potential confounders (age>65, sex, hospital, comorbidities, respiratory capacities)	HCQ alone HCQ+AZ	Group without drug
Sanchez-Alvarez et al(33), 2020	OR=0,471 [0,28,0,792]	No information about adjustments in logistic regression	HCQ alone	Standard care + other antivirals
Singh et al(36), 2020	HR=0,95 [0,74,1,23] HR=1.19 [0.89-1.60]	Creation of groups based on propensity score matching for age, gender, race, confounding comorbidities	HCQ alone HCQ+AZ	Group without HCQ
Yu et al(12), 2020	HR=0,36 [0,18,0,75]	Adjustment: respiratory rate, shortness of breath, alanine aminotransferase (when $p < 0,01$ in univariate Cox model)	HCQ alone	Standard care

Table 1 (continued): Characteristics of studies included in the meta-analysis for COVID-19 mortality

IQ=Interquartile range, SD=Standard Deviation, HCQ=Hydroxychloroquine, AZ=Azithromycine, NA=Not available

^aSome studies did not report mean or median age

^bHR and OR are the most adjusted effect size reported in each study. Some studies did not report effect size. RR_{calculated} were calculated using the number of death in the treatment and the control groups

250 **Study quality**


251
252 Risk of bias was assessed with ROBIN-I for non-randomised studies (n=14) and Rob2 was not
253 applicable for RECOVERY RCT because data were not available (Figure S1). Details on the
254 assessment of studies quality are provided in Fig S2. Among the non-randomized studies, the majority
255 of these observational studies had a high or critical risk of bias (10 out of 16)
256 (12,14,15,20,21,30,32,33,35,36). Five articles had a moderate risk of bias(10,11,13,16,31). Some
257 studies did not report adjusted effect sizes to control confusion and selection bias (15,20,21,32,33,35).
258 Studies quality was lowered by the lack of information about the assignment of treatment, the time
259 between start of follow-up and start of intervention), some unbalanced co-intervention with other
260 antiviral and antibiotic drugs.

261
262 **Hydroxychloroquine and mortality**

263 The pooled RR for COVID-19 mortality was 0.82 (95% CI: 0.62-1.07, $I^2=82$, $P_{\text{heterogeneity}} < 0.01$, n=15)
264 (Figure 2) indicating no significant association between hydroxychloroquine and COVID-19 survival
265 or increased mortality. There was significant high heterogeneity across the included studies ($I^2 = 83\%$,
266 $p < 0.01$). Egger's test ($p = 0.42$) and Begg's test ($P = 0.88$) were not significant for asymmetry of the
267 funnel plot indicating that there is not a major publication bias (Figure S3). In our separated analysis
268 by study design, we found a positive but not significant association between hydroxychloroquine alone
269 and mortality among interventional studies (RR: 1.10, 95%CI: 0.97-1.25, $I^2=0\%$, $P_{\text{heterogeneity within}}=0.5$,
270 n=2); however an inverse but not significant association was found among observational studies (RR:
271 0.78, 95%CI: 0.58-1.05, $I^2=82\%$, $P_{\text{heterogeneity within}} < 0.01$), with heterogeneity observed across the study
272 design ($P_{\text{heterogeneity between}} = 0.03$).

273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300

301
302



303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325

Figure 2: Meta-analysis showing association between hydroxychloroquine alone and COVID-19 mortality. RCT=Randomised Controlled Trial. nRCT=non-Randomised Controlled Trial TE=Estimated treatment effect. seTE=Standard error of treatment estimate. RR=Risk ratio. RR were not adjusted for Alberici et al, Ayerbe et al, Barbosa et al, Sanchez-Alvarez et al and Gautret et al. 95%CI= 95% Confidence Interval

Subgroup analysis for hydroxychloroquine alone

Subgroup analysis among all studies (observational and interventional studies) per study design, type of article (peer-reviewed vs unpublished), risk estimated, age, the exclusion of cancer/haemodialysis patients identified a non-significant association in each subgroup (Table 2).

	N	Pooled Relative Risk	Heterogeneity		
			I ² (%)	P _{within}	P _{between}
HCQ alone					
All Studies	15	0.82 [0.62-1.07]	82%	<0.01	
Study Design					
Observational	13	0.78 [0.58-1.05]	82%	<0.01	0.03
Interventional	2	1.10 [0.97-1.25]	0%	0.48	
Type of article					
Peer-reviewed	10	0.78 [0.53-1.16]	83%	<0.01	0.63
Unpublished	5	0.88 [0.63-1.24]	74%	<0.01	
Adjusted estimate					
Yes	9	0.91 [0.67-1.24]	70%	<0.01	<0.0001
No	5	0.44 [0.35-0.56]	0%	0.41	
Missing	1	1.10 [0.97-1.25]	Not applicable	Not applicable	
Risk estimated					
Reported in the paper	12	0.86 [0.66-1.12]	73%	<0.01	0.9
Calculated	3	0.91 [0.21-3.93]	48%	0.14	
Risk of bias					
Moderate	5	1.02 [0.88-1.18]	0%	0.9	0.19
Serious	6	0.63 [0.38-1.04]	89%	<0.01	
Critical	3	0.97 [0.23-4.07]	31%	0.23	
Continents					
America	6	1.05 [0.93-1.19]	30%	0.2	0.003
Asia	1	0.36 [0.18-0.73]	NA	NA	
Europe	7	0.62 [0.41-0.93]	90%	<0.01	
Multiple	1	1.06 [0.51-2.20]	NA	NA	
Mean daily dose					
Not specified	6	0.58 [0.39-0.85]	80%	<0.01	0.007
<500 mg/d	4	0.97 [0.55-1.69]	84%	<0.01	
>500 mg/d	5	1.09 [0.98-1.22]	0%	0.88	
Age					
63 years or less	7	0.90 [0.65-1.26]	53%	<0.05	0.1
64 years or more	7	0.69 [0.43-1.10]	88%	<0.01	
Not specified	1	1.10 [0.97-1.07]	NA	NA	
Cancer or haemodialysis patient based-population					
No	12	0.87 [0.64-1.18]	84%	<0.01	0.26
Yes	3	0.61 [0.35-1.06]	43%	0.17	
Influence analysis (exclusion of Yu et al, Magagnoli et al, Membrillo et al, Ayerbe et al)	11	1.00 [0.90-1.12]	29%	0.17	
HCQ+AZI					
All Studies	6	1.33 [0.91-1.91]	75%	<0.01	
Study Design					
Observational	6	1.33 [0.91-1.91]	75%	<0.01	
Interventional	0				

Type of article					
Peer-reviewed	4	1.55 [0.86-2.80]	76%	<0.01	0.2
Unpublished	2	1.07 [0.88-1.30]	0%	0.35	
Adjusted estimate					
Yes	6	1.33 [0.91-1.91]	75%	<0.01	
No	0				
Risk estimated					
Reported in the paper	6	1.33 [0.91-1.91]	75%	<0.01	
Calculated	0				
Risk of bias					
Moderate	3	1.54 [0.80-2.95]	86%	<0.01	0.06
Serious	2	1.22 [0.95-1.57]	0%	0.7	
Critical	1	0.02 [0.00-0.73]	NA	NA	
Continents					
America	3	1.10 [0.91-1.32]	0%	0.48	0.0009
Asia	0				
Europe	2	0.24 [0.00-13.43]	80%	0.02	
Multiple	1	2.93 [1.79-4.79]	NA	NA	
Mean daily dose					
Not specified	3	0.75 [0.08-7.21]	87%	<0.01	0.7
<500 mg/d	3	1.10 [0.87-1.38]	0%	0.43	
>500 mg/d	0				
Age					
63 years or less	2	1.22 [0.94-1.58]	0%	0.69	0.9
64 years or more	4	1.30 [0.62-2.71]	85%	<0.01	
Cancer or haemodialysis patient based-population					
No	6	1.33 [0.91-1.91]	75%	<0.01	
Yes	0				

326

327 Table 2. Subgroup analysis for the associations between HCQ alone or HCQ associated with AZI and
328 mortality risk of patients with COVID-19 (observational and interventional studies)

329 N: number of studies. NA: Not applicable for a single study

330

331

332 Test for subgroup differences (observational vs nRCT vs RCT) was not significant (P=0.09)
333 suggesting no differences in the overall effect according to the design of the studies. The pooled RR
334 for observational studies was 0.78 (95%CI: 0.58-1.05, I²=82%, P_{heterogeneity within} <0.01, n=13) and RR
335 was 3.42 (95%CI: 0.15-77.20, n=1) for non-randomized controlled trial and 1.10 (95%CI: 0.97-1.25,
336 n=1) for the RECOVERY randomized controlled trial (Figure 2).

337

338 After stratification by the level of bias from ROBIN-I evaluation, the association between
339 hydroxychloroquine and COVID-19 mortality remained non-significant. The broadness of 95% CI and

340 heterogeneity increased with the risk of bias: moderate risk of bias (RR=1.02 [0.88-1.18], $I^2=0$,
 341 $P_{\text{heterogeneity within}}=0.9$, n=5), serious risk of bias (RR=0.63, 95% CI: (0.38-1.04, $I^2=89\%$, $P_{\text{heterogeneity within}}$
 342 <0.01 , n=6)) and critical risk of bias (RR=0.97, 95% CI: (0.23-4.07, $I^2=31\%$, $P_{\text{heterogeneity within}}=0.2$,
 343 n=3)) (Figure S4).

344
 345 In our stratified analysis by continents (Figure S5), interestingly, we found a significant decreased risk
 346 of mortality with HCQ alone among Asian (RR_{Asia}=0.36, 95%CI: 0.18-0.73, n=1) and European
 347 studies (RR_{Europe}=0.62 (95%CI: 0.41-0.93, $I^2=90\%$, $P_{\text{heterogeneity within}} <0.01$, n=7)) but there was no
 348 significant association among American studies, with heterogeneity detected across continent
 349 ($P_{\text{heterogeneity between}}=0.003$).

350
 351 Furthermore, we found no association between HCQ alone and mortality by HCQ daily mean dose.
 352 The pooled RR was 1.09 (95%CI: 0.98-1.22, $I^2=0\%$, $P_{\text{heterogeneity within}}=0.9$, n=5), for studies with
 353 $>500\text{mg}$, (RR=0.97 (95%CI: 0.55-1.69, $I^2=84\%$, $P_{\text{heterogeneity within}} <0.01$, n=4) for HCQ dose $<500\text{ mg}$
 354 and (RR=0.58 (95%CI: 0.39-0.85, $I^2=80\%$, $P_{\text{heterogeneity within}} <0.01$, n=6) for an unspecified dose of
 355 HCQ, with heterogeneity detected across HCQ dose categories ($P_{\text{heterogeneity between}}=0.007$).


356
 357 In our stratified analysis by studies which reported adjusted effect sizes (vs non-adjusted), the pooled
 358 RR for adjusted estimates was RR=0.91 (95%CI: 0.67-1.24, $I^2=70\%$, $P_{\text{heterogeneity within}} <0.01$, n=9) and
 359 for non-adjusted estimates RR=0.44 (95%CI: 0.35-0.56, $I^2=0\%$, $P_{\text{heterogeneity within}} <0.41$, n=5), suggesting
 360 differences in the overall effect according to the presence of adjustment on potential confounders.

361
 362 Influence analysis showed that Yu et al, Membrillo et al, Ayerbe et al, Magagnoli et al are influent
 363 studies (Figure S7). Removing these studies make heterogeneity decrease at $I^2=0\%$ but the results
 364 remained non-significant (RR=1.00 (95% CI: 0.0-1.13, $I^2=29\%$, n=11) (Table 2).

365
 366 All the results remained similar after exclusion of the two interventional studies (Table S1).

367
 368 **Hydroxychloroquine with azithromycin and mortality**

369 The pooled RR for COVID-19 mortality was 1.33 (95% CI: 0.91-1.921, n=6) (Figure 3) indicating no
 370 significant association between hydroxychloroquine with azithromycin and survival. There was
 371 significant high heterogeneity across the included studies ($I^2=75\%$, $p <0.01$). Egger's test ($p=0.9$) and
 372 Begg's test ($p=0.6$) were not significant but the asymmetry in the funnel plot indicates that there could
 373 be a publication bias. However, the number of included studies is small.



375
 376 Figure 3: Meta-analysis showing association between hydroxychloroquine with azithromycin and
 377 COVID-19 mortality. TE=Estimated treatment effect. seTE=Standard error of treatment estimate.
 378 RR=Risk ratio. 95%CI= 95% Confidence Interval

379

380 **Subgroup analysis for hydroxychloroquine with azithromycin**

381 In all the subgroup analysis (type of article, effect size, risk of bias, continent, mean daily dose, age,
382 exclusion of cancer and haemodialysis patients, influence analysis), no significant association between
383 hydroxychloroquine with azithromycin and mortality was found (Table 2). Nevertheless, in our
384 stratified analysis by continents, we found no significant association with COVID-19 survival risk
385 among American studies (RR=1.10, 95%CI: 0.91-1.32, $I^2=0\%$, $P_{\text{heterogeneity within}}=0.48$, $n=3$) and
386 European studies (RR=0.24 (95%CI: 0.00-13.43, $I^2=80\%$, $P_{\text{heterogeneity within}} < 0.02$, $n=2$)) but there was a
387 significant increased risk of mortality in the multiple countries (RR=2.93, 95%CI: 1.79-4.79, $n=1$),
388 with heterogeneity detected across continent ($P_{\text{heterogeneity between}}=0.0009$).

389

390

391 **Discussion**

392 This meta-analysis summarized the results of 14 observational studies, 1 non-randomised study and 1
393 unpublished randomised controlled trial on hydroxychloroquine with or without azithromycin and
394 COVID-19 survival (Table 1). The results indicated that hydroxychloroquine with or without
395 azithromycin is ineffective to reduce COVID-19 mortality risk in hospitalized patients (Figure 2 and
396 3). Eight observational studies reported no advantage for hydroxychloroquine
397 (10,11,13,16,20,21,31,32). One US Veterans study identified an increased risk of death(30). Three
398 Spanish and one Chinese studies reported a protective effect (12,14,15,33) but this benefit on survival
399 was not replicated in two RCT, especially RECOVERY Trial which is one of the largest study. Our
400 meta-analysis reported a high heterogeneity. The use of an adjusted effect size to control confusion
401 bias, the daily HCQ dose, the risk of bias and the localisation of the study (by continents) may explain
402 one part of the heterogeneity observed according to our subgroup analysis.

403

404 Subgroup analysis revealed that there was a decreased risk of death among 6 European non-
405 randomised studies, one observation Asian study and for studies which did not specify the treatment
406 dose. However, five (14,15,21,32,33) of these European studies have a serious or critical risk of bias
407 (Figure S1). This significant relationship could be explained by a high risk of confusion bias since
408 these articles did not reported adjusted effect size. These studies also have several biases, such as a
409 selection bias Gautret et al, control and treatment groups did not come from the same hospital. In 3
410 Spanish studies (14,15,33), there was no information when treatment were administrated and when the
411 follow-up began which may lead to a bias in selection. Studies with an adjusted HR in figure S5 and
412 with a higher quality reported a non-significant higher RR than the other studies. In this meta-analysis,
413 the majority of the included studies had a high or critical risk of bias (10 out of 16) (Figure S1 and S2).
414 Most of them do not always report the concomitant use of antiviral or antibacterial drugs. In our
415 subgroup analysis by study design, we found inconsistent results with a positive but not significant
416 association between hydroxychloroquine alone and mortality among interventional studies and an
417 inverse but not significant association among observational studies (Table 2). Heterogeneity between
418 these subgroups was observed across the study design. However, these findings are limited by the very
419 low number of interventional studies.

420

421 Two Chinese randomised controlled trial reported no death in both treatment and control group
422 (38,39) and thus their results were not included in our meta-analysis. A previous review on 8 studies
423 (11–14,20,30,39,40) on COVID-19 concluded that the level of evidence for hydroxychloroquine effect
424 is very weak(41). A preprint meta-analysis, using routinely collected records from clinical practice in
425 Germany, Spain, the UK, Japan, and the USA, compared the use of HCQ vs sulfasalazine (42). This
426 study observed an increased risk of 30-day cardiovascular mortality (HR=2.19 [1.22-3.94]) but there
427 was no standard care comparative group. Some previous meta-analyses were also conducted on
428 hydroxychloroquine and various health endpoints including mortality. However these studies did not
429 report all the published and unpublished literature, including a very limiting number of studies: from 3
430 articles(17,18) to 6 articles(19). These previous meta-analyses did not perform subgroup and

431 sensitivity analysis to test the effect of pooling RCT and observational study, neither studying the
432 source of heterogeneity. They used unadjusted risk ratio (calculated with the number of events in each
433 group) whereas in our meta-analysis, we used adjusted relative risk (43) and we did sensitivity
434 analysis on the adjustment of effect size. Statistical adjustments for key prognostic variables allow to
435 limit confusion bias, especially in observational studies which are not randomised. Our meta-analysis
436 confirmed the partial preliminary results of these meta-analyses about the absence of effect for HCQ
437 on survival.

438
439 Our study has several strengths. To our knowledge, this is the first meta-analysis using adjusted
440 relative risk and including numerous subgroup analysis (by continent, population age, effect size, risk
441 of bias, published articles, mean daily dose of hydroxychloroquine, exclusion of cancer and
442 haemodialysis patients) which found stable and consistent results. This study informs clinicians and
443 patients regarding the efficiency of HCQ in treating COVID-19. We included several unpublished
444 papers to minimize the publication bias. Our subgroup analysis by published studies (vs unpublished
445 studies) identified that the inclusion of preprints did not change the results. Exclusion of grey literature
446 (unpublished studies, with limited distribution) could lead to an exaggeration of the intervention effect
447 by 15% (44). There is limited evidence to identify whether grey studies have a poorer methodological
448 quality than published studies(45). Mortality is a reliable endpoint across studies. Limitations come
449 from the studies which do not report adjusted effect size when mortality was not the primary endpoint.
450 Confounding bias is high in these articles (mainly for the preprints). This meta-analysis was based on
451 aggregated data, without access to original patient data. Most of studies are observational which do not
452 allow to identify a causal association. This meta-analysis did not include results from the European
453 DISCOVERY trial and the WHO SOLIDARITY trial (46). To finish, some of the included studies had
454 very low quality of evidence (missing data, small sample size, confusion bias, bias in classification of
455 intervention and selection bias) but the exclusion of these articles did not change the results.

456
457 Few peer-reviewed studies with a comparative group analysed some other endpoints such as
458 virological clearance, clinical improvement and arrhythmia risks. A recent randomized controlled trial
459 with 821 asymptomatic participants in contact with a COVID-19 confirmed case, concluded
460 hydroxychloroquine was not efficient to prevent illness in a prophylactic way (47). However, this trial
461 had a limitation: only 16 participants had a confirmed positive RT-PCR test. A small French non-
462 randomised trial identified a higher proportion of negative RT-PCR tests in the HCQ group (21) but
463 two other RCT did not find any difference between the HCQ and standard care groups for clinical
464 improvement (38,39).

465
466 Several studies raised concerns about an increase of the QTc interval with HCQ use in an intensive
467 care unit (48) and hospitalized patients (11,49). However, this side effect was not found in Tang et al.
468 RCT. Several national health organisations (US FDA Food and Drug Administration(50), French
469 Agency for the Safety of Health Products ANSM (51), European Medicine Agency EMA(52)) raised
470 concerns about using this unapproved drug for COVID-19. ANSM et US FDA removed the
471 authorization for its use outside of clinical trials. The Indian Council of Medical Research took an
472 opposite position and recommend chemoprophylaxis with hydroxychloroquine for asymptomatic cases
473 (53). In an open label, randomised controlled trial with hydroxychloroquine in patient with mild and
474 moderate symptoms, no death were reported (38). Finally, in the comparative peer-reviewed studies, a
475 clear conclusion on hydroxychloroquine is not possible due to the small sample size, the lack of well-
476 performed randomised controlled trials (mainly non-randomised and retrospective studies) and
477 inconsistent results. Many preprints without comparative group and without randomization bring
478 confusion in this highly politicised topic. There is a gap between the speed of clinical research and the
479 expectation of a clear solution to treat COVID-19 patients. Indeed, producing robust clinical trials is
480 necessarily time-consuming. Results from large RCT are needed to shut down the controversy.

481

482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523

Conclusion

In conclusion, there is no strong evidence supporting a benefice for hydroxychloroquine with or without azithromycin to improve survival of COVID-19 hospitalized patients. Conversely, there is no strong evidence supporting an increased mortality associated with HCQ or HCQ + AZ intake.

References

1. Hill A, Wang J, Levi J, Heath K, Fortunak J. Minimum costs to manufacture new treatments for COVID-19. *J Virus Erad.* 2020 Apr 30;6(2):61–9.
2. DeJong C, Wachter RM. The Risks of Prescribing Hydroxychloroquine for Treatment of COVID-19—First, Do No Harm. *JAMA Intern Med* [Internet]. 2020 Apr 29 [cited 2020 Jun 17]; Available from: <https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2765360>
3. Maisonnasse. Hydroxychloroquine in the treatment and prophylaxis of SARS-CoV-2 infection in non-human primates. 2020 May 6 [cited 2020 May 30]; Available from: <https://www.researchsquare.com/article/rs-27223/v1>
4. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). *Clin Infect Dis* [Internet]. [cited 2020 May 30]; Available from: <https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa237/5801998>
5. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Discovery.* 2020 Mar 18;6(1):1–4.
6. Andreani J, Le Bideau M, Duflot I, Jardot P, Rolland C, Boxberger M, et al. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. *Microb Pathog.* 2020 Apr 25;145:104228.
7. Al-Bari MdAA. Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. *Pharmacol Res Perspect.* 2017 Feb;5(1):e00293.
8. Rosenke K, Jarvis MA, Feldmann F, Schwarz B, Okumura A, Lovaglio J, et al. Hydroxychloroquine Proves Ineffective in Hamsters and Macaques Infected with SARS-CoV-2. *bioRxiv.* 2020 Jun 11;2020.06.10.145144.
9. NIH US National Library of Medicine. *ClinicalTrials.gov* [Internet]. [cited 2020 Jun 17]. Available from: <https://clinicaltrials.gov/ct2/results?cond=hydroxychloroquine+COVID-19&term=&cntry=&state=&city=&dist=>
10. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. *Lancet.* 2020 May 28;
11. Mahévas M, Tran V-T, Roumier M, Chabrol A, Paule R, Guillaud C, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational

- 524 comparative study using routine care data. *BMJ* [Internet]. 2020 May 14 [cited 2020 Jun 8];369.
525 Available from: <https://www.bmj.com/content/369/bmj.m1844>
- 526 12. Yu B, Li C, Chen P, Zhou N, Wang L, Li J, et al. Low dose of hydroxychloroquine reduces fatality
527 of critically ill patients with. *Sci China Life Sci*. 2020 May 15;1–7.
- 528 13. Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational Study of
529 Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med*. 2020 May 7;
- 530 14. Membrillo FJ, Ramírez-Olivencia G, Estébanez M, Dios B de, Herrero MD, Mata T, et al. Early
531 Hydroxychloroquine Is Associated with an Increase of Survival in COVID-19 Patients: An
532 Observational Study. 2020 May 9 [cited 2020 Jun 8]; Available from:
533 <https://www.preprints.org/manuscript/202005.0057/v2>
- 534 15. Ayerbe L, Risco C, Ayis S. The association between treatment with heparin and survival in
535 patients with Covid-19. *J Thromb Thrombolysis*. 2020 May 31;1–4.
- 536 16. Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of
537 Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients
538 With COVID-19 in New York State. *JAMA*. 2020 May 11;
- 539 17. Singh AK, Singh A, Singh R, Misra A. “Hydroxychloroquine in patients with COVID-19: A
540 Systematic Review and meta-analysis.”. *Diabetes Metab Syndr*. 2020 May 12;14(4):589–96.
- 541 18. Sarma P, Kaur H, Kumar H, Mahendru D, Avti P, Bhattacharyya A, et al. Virological and clinical
542 cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-
543 analysis. *J Med Virol*. 2020 Jul;92(7):776–85.
- 544 19. Patel TK, Barvaliya M, Kevadiya BD, Patel PB, Bhalla HL. Does Adding of Hydroxychloroquine to
545 the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a
546 Systematic Review. *J Neuroimmune Pharmacol*. 2020 Jun 9;
- 547 20. Barbosa Joshua, Kaitis Daniel, Freedman Ryan, Le Kim, Lin Xihui. Clinical Outcomes of
548 Hydroxychloroquine in Hospitalized Patients with COVID-19: a Quasi-Randomized Comparative
549 Study [Internet]. Dropbox. 2020 [cited 2020 Jun 8]. Available from:
550 [https://www.dropbox.com/s/urzapkyij542qx5/NEJM_Clinical%20Outcomes%20of%20Hydroxyc
551 hloroquine%20in%20Patients%20with%20COVID19.pdf.pdf.pdf.pdf.pdf.pdf.pdf?dl=0](https://www.dropbox.com/s/urzapkyij542qx5/NEJM_Clinical%20Outcomes%20of%20Hydroxyc%20hloroquine%20in%20Patients%20with%20COVID19.pdf.pdf.pdf.pdf.pdf.pdf.pdf?dl=0)
- 552 21. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and
553 azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
554 *International Journal of Antimicrobial Agents*. 2020 Mar 20;105949.
- 555 22. Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial.
556 *Evid Based Ment Health*. 2019 Nov;22(4):153–60.
- 557 23. The Cochrane Collaboration. Box 9.2.a: Calculation of RR, OR and RD [Internet]. *Cochrane*
558 *Handbook for Systematic Reviews of Interventions*. Part 2: General methods for Cochrane
559 reviews. [cited 2020 Jun 10]. Available from: [https://handbook-5-
560 1.cochrane.org/chapter_9/box_9_2_a_calculation_of_risk_ratio_rr_odds_ratio_or_and.htm](https://handbook-5-1.cochrane.org/chapter_9/box_9_2_a_calculation_of_risk_ratio_rr_odds_ratio_or_and.htm)
- 561 24. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a
562 tool for assessing risk of bias in non-randomised studies of interventions. *BMJ* [Internet]. 2016
563 Oct 12 [cited 2020 Jun 8];355. Available from: <https://www.bmj.com/content/355/bmj.i4919>

- 564 25. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool
565 for assessing risk of bias in randomised trials. *BMJ* [Internet]. 2019 Aug 28 [cited 2020 Jun
566 8];366. Available from: <https://www.bmj.com/content/366/bmj.l4898>
- 567 26. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Controlled Clinical Trials*. 1986 Sep
568 1;7(3):177–88.
- 569 27. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias.
570 *Biometrics*. 1994 Dec;50(4):1088–101.
- 571 28. Viechtbauer W, Cheung MW-L. Outlier and influence diagnostics for meta-analysis. *Res Synth
572 Method*. 2010 Apr;1(2):112–25.
- 573 29. McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app
574 for visualizing risk-of-bias assessments. *Res Synth Methods*. 2020 Apr 26;
- 575 30. Magagnoli J, Narendran S, Pereira F, Cummings TH, Hardin JW, Sutton SS, et al. Outcomes of
576 hydroxychloroquine usage in United States veterans hospitalized with COVID-19. *Med
577* [Internet]. 2020 Jun 5 [cited 2020 Jun 8];0(0). Available from:
578 [https://www.cell.com/med/abstract/S2666-6340\(20\)30006-4](https://www.cell.com/med/abstract/S2666-6340(20)30006-4)
- 579 31. Ip A, Berry DA, Hansen E, Goy AH, Pecora AL, Sinclair BA, et al. Hydroxychloroquine and
580 Tocilizumab Therapy in COVID-19 Patients - An Observational Study [Internet]. *Infectious
581 Diseases (except HIV/AIDS)*; 2020 May [cited 2020 Jun 8]. Available from:
582 <http://medrxiv.org/lookup/doi/10.1101/2020.05.21.20109207>
- 583 32. Alberici F, Delbarba E, Manenti C, Econimo L, Valerio F, Pola A, et al. A report from the Brescia
584 Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis
585 patients with SARS-CoV-2 infection. *Kidney Int*. 2020 May 8;
- 586 33. Sánchez-Álvarez JE, Fontán MP, Martín CJ, Pelicano MB, Reina CJC, Prieto ÁMS, et al. Status of
587 SARS-CoV-2 infection in patients on renal replacement therapy. Report of the COVID-19
588 Registry of the Spanish Society of Nephrology (SEN). *Nefrología (English Edition)* [Internet].
589 2020 Apr 27 [cited 2020 Jun 8]; Available from:
590 <http://www.sciencedirect.com/science/article/pii/S201325142030050X>
- 591 34. Wilkinson E. RECOVERY trial: the UK covid-19 study resetting expectations for clinical trials. *BMJ
592* [Internet]. 2020 Apr 28 [cited 2020 Jun 16];369. Available from:
593 <https://www.bmj.com/content/369/bmj.m1626>
- 594 35. Rogado J, Obispo B, Pangua C, Serrano-Montero G, Martín Marino A, Pérez-Pérez M, et al.
595 Covid-19 transmission, outcome and associated risk factors in cancer patients at the first
596 month of the pandemic in a Spanish hospital in Madrid. *Clin Transl Oncol*. 2020 May 25;1–5.
- 597 36. Singh S, Khan A, Chowdhry M, Chatterjee A. Outcomes of Hydroxychloroquine Treatment
598 Among Hospitalized COVID-19 Patients in the United States- Real-World Evidence From a
599 Federated Electronic Medical Record Network [Internet]. *Infectious Diseases (except HIV/AIDS)*;
600 2020 May [cited 2020 Jun 8]. Available from:
601 <http://medrxiv.org/lookup/doi/10.1101/2020.05.12.20099028>
- 602 37. RECOVERY TRIAL. No clinical benefit from use of hydroxychloroquine in hospitalised patients
603 with COVID-19 — RECOVERY Trial [Internet]. [cited 2020 Jun 8]. Available from:
604 <https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the->

- 605 randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-
606 2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-
607 19
- 608 38. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with
609 mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial.
610 BMJ [Internet]. 2020 May 14 [cited 2020 Jun 8];369. Available from:
611 <https://www.bmj.com/content/369/bmj.m1849>
- 612 39. CHEN Jun LD, CHEN Jun LD. A pilot study of hydroxychloroquine in treatment of patients with
613 moderate COVID-19. *J Zhejiang Univ (Med Sci)*. 2020 Mar 6;49(2):215–9.
- 614 40. Mallat J, Hamed F, Balkis M, Mohamed MA, Mooty M, Malik A, et al. Hydroxychloroquine is
615 associated with slower viral clearance in clinical COVID-19 patients with mild to moderate
616 disease: A retrospective study. medRxiv. 2020 May 2;2020.04.27.20082180.
- 617 41. Hernandez AV, Roman YM, Pasupuleti V, Barboza JJ, White CM. Hydroxychloroquine or
618 Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review. *Ann Intern*
619 *Med*. 2020 May 27;
- 620 42. Lane JCE, Weaver J, Kostka K, Duarte-Salles T, Abrahao MTF, Alghoul H, et al. Safety of
621 hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread
622 use for COVID-19: a multinational, network cohort and self-controlled case series study
623 [Internet]. *Rheumatology*; 2020 Apr [cited 2020 Jun 15]. Available from:
624 <http://medrxiv.org/lookup/doi/10.1101/2020.04.08.20054551>
- 625 43. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4.
626 Rating the quality of evidence—study limitations (risk of bias). *Journal of Clinical Epidemiology*.
627 2011 Apr 1;64(4):407–15.
- 628 44. McAuley L, Pham B, Tugwell P, Moher D. Does the inclusion of grey literature influence
629 estimates of intervention effectiveness reported in meta-analyses? *The Lancet*. 2000 Oct
630 7;356(9237):1228–31.
- 631 45. Hopewell S, McDonald S, Clarke MJ, Egger M. Grey literature in meta-analyses of randomized
632 trials of health care interventions. *Cochrane Database of Systematic Reviews* [Internet]. 2007
633 [cited 2020 Jun 12];(2). Available from:
634 <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.MR000010.pub3/full>
- 635 46. WHO (World Health Organization). “Solidarity” clinical trial for COVID-19 treatments [Internet].
636 [cited 2020 Jun 8]. Available from: [https://www.who.int/emergencies/diseases/novel-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments)
637 [coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments)
638 [covid-19-treatments](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments)
- 639 47. Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A
640 Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. *New*
641 *England Journal of Medicine*. 2020 Jun 3;0(0):null.
- 642 48. Bessière F, Rocca H, Delinière A, Charrière R, Chevalier P, Argaud L, et al. Assessment of QT
643 Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection
644 Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive
645 Care Unit. *JAMA Cardiol* [Internet]. 2020 May 1 [cited 2020 Jun 8]; Available from:
646 <https://jamanetwork.com/journals/jamacardiology/fullarticle/2765633>

- 647 49. Mercurio NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et al. Risk of QT Interval
648 Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant
649 Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019
650 (COVID-19). *JAMA Cardiol* [Internet]. 2020 May 1 [cited 2020 Jun 8]; Available from:
651 <https://jamanetwork.com/journals/jamacardiology/fullarticle/2765631>
- 652 50. Commissioner O of the. Coronavirus (COVID-19) Update: FDA Revokes Emergency Use
653 Authorization for Chloroquine and Hydroxychloroquine [Internet]. FDA. FDA; 2020 [cited 2020
654 Jun 15]. Available from: [https://www.fda.gov/news-events/press-announcements/coronavirus-](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and)
655 [covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and)
- 656 51. Agence Nationale de Sécurité du médicament et des produits de santé (ANSM). COVID-19 :
657 l'ANSM souhaite suspendre par précaution les essais cliniques évaluant l'hydroxychloroquine
658 dans la prise en charge des patients - Point d'Information - ANSM : Agence nationale de
659 sécurité du médicament et des produits de santé [Internet]. [cited 2020 Jun 15]. Available from:
660 [https://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/COVID-19-l-](https://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/COVID-19-l-ANSM-souhaite-suspendre-par-precaution-les-essais-cliniques-evaluant-l-hydroxychloroquine-dans-la-prise-en-charge-des-patients-Point-d-Information)
661 [ANSM-souhaite-suspendre-par-precaution-les-essais-cliniques-evaluant-l-hydroxychloroquine-](https://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/COVID-19-l-ANSM-souhaite-suspendre-par-precaution-les-essais-cliniques-evaluant-l-hydroxychloroquine-dans-la-prise-en-charge-des-patients-Point-d-Information)
662 [dans-la-prise-en-charge-des-patients-Point-d-Information](https://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/COVID-19-l-ANSM-souhaite-suspendre-par-precaution-les-essais-cliniques-evaluant-l-hydroxychloroquine-dans-la-prise-en-charge-des-patients-Point-d-Information)
- 663 52. DIMITROVA EK. COVID-19: reminder of risk serious side effects with chloroquine and
664 hydroxychloroquine [Internet]. European Medicines Agency. 2020 [cited 2020 Jun 15]. Available
665 from: [https://www.ema.europa.eu/en/news/covid-19-reminder-risk-serious-side-effects-](https://www.ema.europa.eu/en/news/covid-19-reminder-risk-serious-side-effects-chloroquine-hydroxychloroquine)
666 [chloroquine-hydroxychloroquine](https://www.ema.europa.eu/en/news/covid-19-reminder-risk-serious-side-effects-chloroquine-hydroxychloroquine)
- 667 53. Rathi S, Ish P, Kalantri A, Kalantri S. Hydroxychloroquine prophylaxis for COVID-19 contacts in
668 India. *The Lancet Infectious Diseases* [Internet]. 2020 Apr 17 [cited 2020 Jun 15];0(0). Available
669 from: [https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(20\)30313-3/abstract](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30313-3/abstract)

670
671
672
673
674
675
676
677
678
679
680
681
682

683 **List of figures and tables**

684 Figure 1: Flow diagram of study selection process

685 Figure 2: Meta-analysis showing association between hydroxychloroquine alone and COVID-19 mortality
686 (observational vs intervention)

687 Figure 3: Meta-analysis showing association between hydroxychloroquine with azithromycin and COVID-19
688 mortality.

689
690 Table 1: Characteristics of studies included in the meta-analysis for COVID-19 mortality

691 Table 2: Subgroup analysis for the associations between HCQ alone or HCQ+AZI and mortality risk of patients
692 with COVID-19 (observational and interventional studies)

693
694

695 **Supplementary tables and figures**

696 Supplementary tables and figures

697 S1 Fig. Summary of risk of bias analysis for non-randomised studies (ROBIN-I)

698 S2 Fig Assessment of quality of studies using ROBIN-I for non-randomised studies.

699 S3 Fig.: Funnel plot for hydroxychloroquine alone and COVID-19 mortality risk

700 S4 Fig. Forest plot for hydroxychloroquine alone and COVID-19 mortality risk, subgroup analysis per risk of bias

702 S5 Fig. Forest plot for hydroxychloroquine alone and COVID-19 mortality risk, subgroup analysis per continent

703 S6 Fig. Forest plot for hydroxychloroquine alone and COVID-19 mortality risk, subgroup analysis per hydroxychloroquine dose

705 S7 Fig. Influence analysis for hydroxychloroquine and COVID-19 mortality

706

707 S1. Full electronic search strategy

708 S2: PRISMA Checklist

709 S1 Table. Subgroup analysis for the associations between HCQ+AZI and mortality risk of patients with COVID-19 (observational studies)

711

712

713

714

715 Figure S1: Summary of risk of bias analysis for non-randomised studies (ROBIN-I)



716

717

718

719

720

721

722

723

724


725

726

727


728

729 Figure S2: Assessment of quality of studies using ROBINS-I for non-randomised studies.




730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760

761 Figure S3: Funnel plot for hydroxychloroquine alone and COVID-19 mortality risk




762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778

779 Figure S4: Forest plot for hydroxychloroquine alone and COVID-19 mortality risk, subgroup
 780 analysis per risk of bias




781
 782
 783
 784
 785
 786
 787
 788
 789
 790
 791
 792
 793
 794
 795
 796

797 Figure S5: Forest plot for hydroxychloroquine alone and COVID-19 mortality risk, subgroup
798 analysis per continent




799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816

817 Figure S6: Forest plot for hydroxychloroquine alone and COVID-19 mortality risk, subgroup
 818 analysis per hydroxychloroquine dose
 819



820
 821
 822
 823
 824
 825
 826
 827
 828
 829
 830
 831
 832
 833
 834
 835
 836
 837
 838
 839
 840

841 Figure S7: Influence analysis for hydroxychloroquine and COVID-19 mortality



842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859

860

861 S1. Full electronic search strategy

862

863 **Cochrane Library**

864 Website: <https://www.cochranelibrary.com/advanced-search>

865 Cochrane Review matching (Hydroxychloroquine or HCQ) in Title Abstract Keyword AND

866 (mortality or death) in Title Abstract Keyword AND (COVID-19 or SRAS-CoV-2) in Title Abstract

867 Keyword - (Word variations have been searched)

868

869 **PubMed**

870 Website:

871 [https://pubmed.ncbi.nlm.nih.gov/pubmed/?term=\(hydroxychloroquine+or+HCQ\)+AND+\(COVID-](https://pubmed.ncbi.nlm.nih.gov/pubmed/?term=(hydroxychloroquine+or+HCQ)+AND+(COVID-19+OR+SARS-CoV-2+OR+coronavirus)+AND+(Mortality+OR+death))

872 [19+OR+SARS-CoV-2+OR+coronavirus\)+AND+\(Mortality+OR+death\)](https://pubmed.ncbi.nlm.nih.gov/pubmed/?term=(hydroxychloroquine+or+HCQ)+AND+(COVID-19+OR+SARS-CoV-2+OR+coronavirus)+AND+(Mortality+OR+death))

873 ((hydroxychloroquine or HCQ) AND (COVID-19 OR SARS-CoV-2 OR coronavirus) AND (Mortality

874 OR death)

875

876 **Web of Science**

877 Website:

878 [http://apps.webofknowledge.com.proxy.insermbiblio.inist.fr/Search.do?product=UA&SID=F6KgcWI](http://apps.webofknowledge.com.proxy.insermbiblio.inist.fr/Search.do?product=UA&SID=F6KgcWI7K6kjXJwhAoH&search_mode=GeneralSearch&prID=9a27b347-ecf8-4832-9206-db1bbd2cc9a8)

879 [7K6kjXJwhAoH&search_mode=GeneralSearch&prID=9a27b347-ecf8-4832-9206-db1bbd2cc9a8](http://apps.webofknowledge.com.proxy.insermbiblio.inist.fr/Search.do?product=UA&SID=F6KgcWI7K6kjXJwhAoH&search_mode=GeneralSearch&prID=9a27b347-ecf8-4832-9206-db1bbd2cc9a8)

880 You searched for: TOPIC: (covid-19 OR SRAS-CoV-2) AND TOPIC: (hydroxychloroquine or HCQ)

881 AND TOPIC: (mortality or death)

882

883 **Manual additional searches:**

884 **MedRxiv**

885 <https://www.medrxiv.org/>

886 Search: Hydroxychloroquine COVID-19 mortality

887 **Google scholar:**

888 [https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=hydroxychloroquine+COVID-](https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=hydroxychloroquine+COVID-19&btnG=)

889 [19&btnG=](https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=hydroxychloroquine+COVID-19&btnG=)

890 Search: Hydroxychloroquine COVID-19 mortality

891

892

893

894

895

896

897

898

899

900

901

902

903 S2. PRISMA Checklist

904

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	p.1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	p.2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	p.3 Lines 110-138
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	p.3 Lines 139-141
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	3 Line 154
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	p.4 Lines 170-187
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	p.3 Lines 146-152
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	p.3 lines 147-152 p.29 S1.
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	p.4 lines 159-164
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	p.4 lines 166-169
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	p.4 lines 170-186

Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	p.4 lines 184-186
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	p.4 lines 171-183
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	p.4-5 lines
Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	p.4 line 202-203
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	p.5 lines 208-218
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	p.5 Fig. 1
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	p. 6-10 Table 1
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	p.23 Supplementary Figures S1 and S2
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	5-7
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	p.11-16 Fig.2-3 Table 2
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	p.11 lines 266-273 p.15 lines 371-374 Figure S3
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	p.13-15 Lines 313-367 p.16 lines 381-389 Table S1
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	p.16 lines 393-437
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g.,	p.17 lines 439-454

		incomplete retrieval of identified research, reporting bias).	
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	P.17 lines 465-486
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	Funding information is entered in the financial disclosure section of the submission system

905

906

907 Table S1: Subgroup analysis for the associations between HCQ+AZI and mortality risk of
 908 patients with COVID-19 (observational studies)

Subgroup analysis for the associations between HCQ and mortality risk of patients with COVID-19 (excluding interventional studies)					
	N	RRpooled	Heterogeneity		
			I ² (%)	P _{within}	P _{between}
HCQ alone					
All Studies	13				
Type of article					
Peer-reviewed	9	0.76 [0.51-1.13]	85%	<0.01	0.84
Unpublished	4	0.81 [0.52-1.27]	72%	0.01	
Adjusted estimate					
Yes	9	0.91 [0.67-1.24]	70%	<0.01	0.0001
No	4	0.44 [0.35-0.55]	0%	0.52	
Risk estimated					
Reported in the paper	11	0.83 [0.61-1.11]	72%	<0.01	0.82
Calculated	2	0.69 [0.15-3.25]	54%	0.14	
Risk of bias					
Moderate	5	1.02 [0.88-1.18]	0%	0.9	0.18
Serious	6	0.63 [0.38-1.04]	89%	<0.01	
Critical	2	0.75 [0.16-3.58]	44%	0.18	
Continents					
America	6	1.05 [0.93-1.19]	30%	0.2	<0.0001
Asia	1	0.36 [0.18-0.73]	NA	NA	
Europe	5	0.45 [0.37-0.55]	0%	0.47	
Multiple	1	1.06 [0.51-2.20]	NA	NA	
Mean daily dose					
Not specified	6	0.58 [0.39-0.85]	80%	<0.01	0.029
<500 mg/d	4	1.06 [0.84-1.33]	0%	0.75	
>500 mg/d	3	0.58 [0.39-0.85]	80%	<0.01	
Age					
63 years or less	6	0.89 [0.64-1.24]	59%	0.03	0.39
64 years or more	7	0.69 [0.43-1.10]	89%	<0.01	

Cancer or hemodialysis patient based-population					
No	10	0.83 [0.59-1.18]	85%	<0.01	0.34
Yes	3	0.61 [0.35-1.06]	43%	0.17	
Influence analysis (exclusion of Yu et al, Magagnoli et al, Membrillo et al, Ayerbe et al)	9	0.95 [0.84-1.08]	27%	0.20	

909

910

911

912

913

914

915

916

917

918

919

920

921

922

923

924

925

926

927

928

929

930